Intellia Therapeutics short interest was 39.28% of the float on April 30th, according to new data we received from Benzinga. Short interest totaled 43,531,487 shares, which was an increase of 12.16% from April 15th.
It is estimated that it would take 4.31 days for short sellers to buy back their shares, with current trading volumes.
Intellia Therapeutics Hedge Fund Activity
We have seen 178 institutional investors add shares of Intellia Therapeutics stock to their portfolio, and 122 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONTRARIUS GROUP HOLDINGS LTD removed 5,175,456 shares (-87.9%) from their portfolio in Q4 2025, for an estimated $46,527,349
- MORGAN STANLEY removed 3,694,724 shares (-61.3%) from their portfolio in Q4 2025, for an estimated $33,215,568
- D. E. SHAW & CO., INC. added 3,102,664 shares (+139.2%) to their portfolio in Q4 2025, for an estimated $27,892,949
- BAKER BROS. ADVISORS LP removed 2,746,674 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $24,692,599
- ARK INVESTMENT MANAGEMENT LLC added 2,288,146 shares (+19.2%) to their portfolio in Q4 2025, for an estimated $20,570,432
- VANGUARD GROUP INC added 1,965,181 shares (+17.8%) to their portfolio in Q4 2025, for an estimated $17,666,977
- UBS GROUP AG added 1,829,934 shares (+212.9%) to their portfolio in Q1 2026, for an estimated $23,459,753
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Intellia Therapeutics Insider Trading Activity
Intellia Therapeutics insiders have traded $NTLA stock on the open market 12 times in the past 6 months. Of those trades, 1 have been purchases and 11 have been sales.
Here’s a breakdown of recent trading of $NTLA stock by insiders over the last 6 months:
- FRED E COHEN purchased 150,000 shares for an estimated $1,402,500
- JOHN M LEONARD (President and CEO) has made 0 purchases and 4 sales selling 122,292 shares for an estimated $1,150,869.
- JAMES BASTA (EVP, General Counsel) has made 0 purchases and 2 sales selling 11,608 shares for an estimated $112,443.
- DAVID LEBWOHL (EVP, Chief Medical Officer) sold 11,903 shares for an estimated $109,626
- ELIANA CLARK (EVP, Chief Technical Officer) sold 9,515 shares for an estimated $87,633
- BIRGIT C SCHULTES (EVP, Chief Scientific Officer) sold 8,508 shares for an estimated $78,358
- EDWARD J III DULAC (EVP, Chief Financial Officer) sold 6,379 shares for an estimated $58,750
- MICHAEL P DUBE (VP, Chief Accounting Officer) sold 2,989 shares for an estimated $27,528
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Intellia Therapeutics Price Targets
Multiple analysts have issued price targets for $NTLA recently. We have seen 11 analysts offer price targets for $NTLA in the last 6 months, with a median target of $29.0.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $15.0 on 04/28/2026
- Silvan Turkcan from Citizens set a target price of $30.0 on 04/28/2026
- Salveen Richter from Goldman Sachs set a target price of $9.0 on 04/28/2026
- Whitney Ijem from Canaccord Genuity set a target price of $58.0 on 04/28/2026
- Geulah Livshits from Chardan Capital set a target price of $30.0 on 04/27/2026
- Jack Allen from Baird set a target price of $13.0 on 04/27/2026
- Debanjana Chatterjee from Jones Trading set a target price of $29.0 on 03/04/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
